SCHEMBL1471054

SCHEMBL1471054

CC(C)(C)OC(=O)N(CCNc1ccccc1N)Cc1cc(C(=O)N2CCCCC2)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.37
HPGD P15428 4/20 0.37
MAPK1 P28482 2/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 3/20 0.37
USP2 O75604 1/20 0.37
ALOX15 P16050 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
ABL1 P00519 1/20 0.33
RIN1 Q13671 1/20 0.33
GLA P06280 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1470682 0.89 HRH3 (0.40) CNR2HPGDMAPK1MAPTALDH1A1
SCHEMBL1470893 0.87 SMN1; SMN2 (0.40) CNR2HPGDMAPK1MAPTALDH1A1
SCHEMBL1470736 0.86 NPC1 (0.41) CNR2HPGDMAPTALDH1A1HDAC1
SCHEMBL1470738 0.78 HPGD (0.42) HPGDMAPK1MAPTALDH1A1USP2
SCHEMBL1470908 0.75 HTR1A (0.42) CNR2HPGDALDH1A1HDAC1NPC1
SCHEMBL1471319 0.75 HDAC1 (0.50) HDAC3HDAC1HDAC2
SCHEMBL1471446 0.74 HDAC1 (0.41) CNR2HPGDALDH1A1TDP1TSHR
SCHEMBL1470751 0.73 SMN1; SMN2 (0.42) CNR2HPGDMAPK1MAPTALDH1A1
SCHEMBL1471442 0.73 HTR1A (0.52) KMT2A
SCHEMBL5695821 0.72 RAB9A (0.43) HPGDMAPK1MAPTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20080009521-A1 Aryl Piperidine Amides HUANG CHARLES Q 2008-01-10 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
EP-1660472-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
WO-2005021525-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-10 WO disclosed
US-20050049239-A1 Aryl piperidine amides JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009521-A1 Aryl Piperidine Amides BDNF, NTRK2, OPRL1 CNR2 67/4885HPGD 3042/4885MAPK1 1699/4885
US-20050049239-A1 Aryl piperidine amides BDNF, NTRK2, OPRL1 CNR2 67/4885HPGD 3042/4885MAPK1 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.